Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging

Acta Oncologica

Volumn 42, Issue 2, 2003, Pages 123-136

  Brahme, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; PHOTONS; POSITRONS; RADIOTHERAPY; TUMORS;

VIVO PREDICTIVE ASSAYS;

MEDICAL IMAGING;

ACCURACY; ALGORITHM; ASSAY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DOSE RESPONSE; ENERGY; EQUIPMENT; ERROR; GEOMETRY; HYPOXIA; IN VIVO STUDY; LIGHT; PHOTON; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION BEAM; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOSENSITIVITY; TREATMENT PLANNING; TUMOR CELL;

HUMANS; IMAGING, THREE-DIMENSIONAL; NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038364064     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004986     Document Type: Conference Paper

References (40)

1. Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003; 55: 5-15.
2. Forssell Aronson E, Kjellén E, Mattson S, Hellström M. Medical imaging for improved tumour characterization, delineation and treatment verification. Acta Oncol 2002; 41: 604-14.
3. Townsend DW. Imaging function and anatomy with a combined PET-CT scanner. Paper presented at Queens Medical Center, Honolulu, March 28, 2002. See also Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol 2001; 11: 1968-74.
4. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer 2002; 2: 683-93.
5. Sullivan DC, Hoffman JM. In vivo imaging of gene expression. Sem Radiat Oncol 2001; 11: 37-46.
6. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53 dependent genes with positron emission tomography in vivo. PNAS 2001; 98: 9300-5.
7. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Sem Oncol 2002; 29: 246-57.
8. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19: 3745-9.
9. Kiricuta IC. Ed. Proc First Int Symp on Target Volume Definition in Radiation Oncology. Inst of Radiat Oncol, St Vincenz-Hospital, Limburg, Germany, 2001.
10. Janek S. 3-Dimensional patient dose delivery verification based on PET-CT imaging of photonuclear reactions in 50 MV scanned photon beams. MSc thesis, Dept. Med Rad Phys, Karolinska Institutet and Royal Institute of Technology 2002.
11. Brahme A, Källman P, Lind B. Optimization of proton and heavy ion therapy using an adaptive inversion algorithm. Radiother Oncol 1988; 15: 189-97.
12. Brahme A, Källman P, Lind B. Optimization of the probability of achieving complication free tumor control using a 3D pencil beam scanning technique for protons and heavy ions. Proc Tokyo, World Congr Med Phys Biomed Engineer, Kyoto, Japan, July 7-12, 1991.
13. Brahme A, Källman P, Tilikidis A. Developments in ion beam therapy planning and treatment optimization. In: Linz U, ed. Ion beams in tumor therapy. Chapman & Hall: Weinheim; 1995. p. 290-9.
14. Löf J, Liander A, Kåver G, Lind BK, Brahme A. ORBIT - a general object oriented code for radiotherapy optimization. Radiother Oncol 1998; 48(Suppl 1): S69.
15. Kraft G. Tumor therapy with heavy charged particles. Prog Part Nucl Phys 2000; 45: S473-544.
16. Tsujii H, Morita S, Miyamoto T, et al. Experiences of carbon ion radiotherapy at NIRS. In: Kogelnik HD, Lukas P, Sedlmayer F, eds. Progress in radio-oncology VII. Bologna, Italy: Monduzzi Editore; 2002. p. 393-405.
17. Brahme A. Development of radiobiologically based therapy optimization and target definition. Kiricuta IC, ed. Proc Second Int Symp on Target Volume Definition in Radiation Oncology. Inst Radiat Oncol, St Vincenz-Hospital, Limburg, Germany, 2002.
18. Nilsson J, Lind BK, Brahme A. Radiation response of hypoxic and generally heterogeneous tissues. Int J Radiat Biol 2002; 78: 389-405.
19. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol 1984; 23: 379-91.
20. Lind BK, Persson LM, Edgren MR, Hedlöf I, Brahme A. Repairable conditionally repairable damage model based on dual Poisson processes. Radiat Res 2003; 159.
21. Erdi YE, Macapinlac H, Rosenzweig KE, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000; 7: 861-6.
22. Tureson I, Bernefors R, Book M, et al. Normal tissue response to low doses of radiotherapy assessed by molecular markers. Acta Oncol 2001; 40: 941-51.
23. Glashan JC. Notes on the Quintic. Am J Mathematics 1884; 7: 178-9.
24. Brahme A, Ågren A. On the optimal dose distribution for eradication of heterogeneous tumors. Acta Oncol 1987; 26: 377-85.
25. Brahme A. Treatment optimization using physical and biological objective functions. In: Smith A, ed. Radiation therapy physics. Berlin: Springer; 1995. p. 209-46.
26. Brahme A, Lewensohn R, Ringborg U, Amaldi U, Gerardi F, Rossi S. Design of a centre for biologically optimised light ion therapy in Stockholm. Nucl Instr Meth Phys Res 2001a; B184: 569-88.
27. Brahme A, Nilsson J, Belkic D. Biologically optimized radiation therapy. Acta Oncol 2001; 40: 725-34.
28. Brahme A. Development of radiation therapy optimization. Acta Oncol 2000; 39: 579-95.
29. Brahme A. Individualizing cancer treatment: biological optimization models in treatment planning and delivery. Int J Radiat Oncol Biol Phys 2001; 49: 327-37.
30. Brahme A. Biologically based treatment planning. In: Mustakallio Centennial Symposium Helsinki. Acta Oncol 1999; (Suppl. 13): 61-8.
31. Ågren A, Brahme A, Turesson I. Optimization of uncomplicated control for head and neck tumors. Int J Radiat Oncol Biol Phys 1990; 19: 1077-85.
32. Ågren Cronqvist A, Källman P, Turesson I, Brahme A. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours. Acta Oncol 1995; 34: 851-60.
33. Brahme A. Optimized radiation therapy based on radiobiological objectives. Sem Oncol 1999; 9: 35-47.
34. Lind BK, Nilsson J, Löf J, Brahme A. Generalization of the normalized dose-response gradient to non-uniform dose delivery. Acta Oncol 2001; 40: 719-24.
35. Nordell B. Production of photoneutron beams and radionuclides by photonuclear reactions using a 50 MeV racetrack microtron. Thesis, Stockholm University, 1983.
36. Nüssbaum GH, Purdy JA, Granada CO, Emami B, Sapareto SA. Use of the Clinac-35 for tissue activation in non-invasive measurements of capillary blood-flow. Med Phys 1983; 10: 4.
37. Sobolevski N, Gudowska I, Andreo P, Belkic D and Brahme A. Interaction of ion beams with tissue-like media; simulations with the SHIELD-HIT Monte-Carlo transport code. Proc Shielding Aspects of Accelerators. Stanford Linear Accelerator Center, California, 2002.
38. Kåver G, Lind BK, Löf J, Liander A, Brahme A. Stochastic optimization of intensity modulated radiotherapy to account for uncertainties in patient sensitivity. Phys Med Biol 1999; 44: 2955-69.
39. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 11: 1334-6.
40. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol Suppl 2001; 96S-103S.